Antengene to Present Selinexor Data from Late-Stage Trials at ASH 2024
核心洞察
Antengene (搜索) will present Phase III results of weekly selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in Chinese patients with relapsed/refractory multiple myeloma (搜索).
Preliminary results from a Phase I/II study of selinexor combined with tislelizumab in relapsed/refractory extranodal NK/T-cell lymphoma (搜索) will also be presented.
The presentations highlight selinexor's potential in treating hematologic malignancies through its novel mechanism of action targeting the nuclear export protein XPO1 (搜索).
Antengene (搜索) Corporation Limited will present new data from two clinical studies of selinexor at the 2024 American Society of Hematology (ASH) Annual Meeting, held December 7-10 in San Diego, CA. The presentations will feature results from a Phase III trial in relapsed/refractory multiple myeloma (搜索) (RRMM) and a Phase I/II study in relapsed/refractory extranodal NK/T-cell lymphoma (搜索) (R/R ENKTL). These data presentations underscore the potential of selinexor as a therapeutic option for patients with hematologic malignancies.
Selinexor in Relapsed/Refractory Multiple Myeloma
The Phase III study, named Bench study, investigates weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in Chinese patients with RRMM. The primary analysis of this study will be presented in a poster session.
The details of the poster are as follows:
- Title: Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase III Bench Study
- Publication Number: 4748
- Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster III
- Date: Monday, December 9, 2024
- Time: 6:00 PM - 8:00 PM (Eastern time)
- First Author: Dr. Jin Lu (Peking University People's Hospital)
- Corresponding Author: Dr. Jian Hou (Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine)
Selinexor in Relapsed/Refractory Extranodal NK/T-Cell Lymphoma
Antengene (搜索) will also present preliminary results from Arm C of the TOUCH study, a multicenter, single-arm, Phase I/II trial evaluating selinexor combined with tislelizumab in patients with R/R ENKTL. This presentation will provide insights into the efficacy and safety of this combination therapy in a difficult-to-treat patient population.
The details of the poster are as follows:
- Title: Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch
- Publication Number: 4448
- Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III
- Date: Monday, December 9, 2024
- Time: 6:00 PM - 8:00 PM (Eastern time)
- First Author: Dr. Rong Tao (Fudan University Shanghai Cancer Center)
- Corresponding Author: Dr. Huiqiang Huang (Sun Yat-Sen University Cancer Center)
About Selinexor
XPOVIO® (selinexor) is an orally available, selective inhibitor of nuclear export (SINE) compound. By blocking the nuclear export protein XPO1 (搜索), selinexor promotes the accumulation and activation of tumor suppressor proteins within the nucleus, downregulating oncogenic protein levels. This unique mechanism of action allows selinexor to exert antitumor effects and restore hormone sensitivity. Antengene (搜索) is currently evaluating selinexor in multiple clinical studies in mainland China for various relapsed/refractory hematologic malignancies and solid tumors.